Ulrik Niels Lassen

Ulrik Niels Lassen

Clinical Professor

Member of:

  • Clinical Oncology


Publication year:
All
1 - 10 out of 13Page size: 10
  1. 2018
  2. Published

    Circulating tumor DNA as a marker of treatment response in BRAF V600E mutated non-melanoma solid tumors

    Ahlborn, L. B., Tuxen, I. V., Mouliere, F., Kinalis, S., Schmidt, A. Y., Rohrberg, K. S., Santoni Rugiu, Eric, Nielsen, Finn Cilius, Lassen, Ulrik Niels, Yde, C. W., Oestrup, O. & Mau-Sorensen, M., 2018, In: OncoTarget. 9, 66, p. 32570-32579

    Research output: Contribution to journal › Journal article › Research › peer-review

  3. Published

    Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children

    Drilon, A., Laetsch, T. W., Kummar, S., DuBois, S. G., Lassen, U. N., Demetri, G. D., Nathenson, M., Doebele, R. C., Farago, A. F., Pappo, A. S., Turpin, B., Dowlati, A., Brose, M. S., Mascarenhas, L., Federman, N., Berlin, J., El-Deiry, W. S., Baik, C., Deeken, J., Boni, V. & 18 others, Nagasubramanian, R., Taylor, M., Rudzinski, E. R., Meric-Bernstam, F., Sohal, D. P. S., Ma, P. C., Raez, L. E., Hechtman, J. F., Benayed, R., Ladanyi, M., Tuch, B. B., Ebata, K., Cruickshank, S., Ku, N. C., Cox, M. C., Hawkins, D. S., Hong, D. S. & Hyman, D. M., 2018, In: The New England Journal of Medicine. 378, 8, p. 731-739

    Research output: Contribution to journal › Journal article › Research › peer-review

  4. Published

    Patient information in phase 1 trials: A systematic review

    Gad, K. T., Lassen, Ulrik Niels, Mau-Søerensen, M., Høybye, M. T. & Johansen, Christoffer, Mar 2018, In: Psycho-Oncology. 27, 3, p. 768-780

    Research output: Contribution to journal › Review › Research › peer-review

  5. Published

    Outcome of Bevacizumab Therapy in Patients with Recurrent Glioblastoma Treated with Angiotensin System Inhibitors

    Johansen, M. D., Urup, T., Holst, C. B., Christensen, I. J., Grunnet, K., Lassen, Ulrik Niels, Friis, S. & Poulsen, H. S., 2018, In: Cancer Investigation. 36, 9-10, p. 512-519 8 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  6. Published

    TRK Inhibition: A New Tumor-Agnostic Treatment Strategy

    Kummar, S. & Lassen, Ulrik Niels, 2018, In: Targeted Oncology. 13, 5, p. 545-556

    Research output: Contribution to journal › Review › Research › peer-review

  7. Published

    First-in-human study of LY3039478, an oral Notch signaling inhibitor in advanced or metastatic cancer

    Massard, C., Azaro, A., Soria, J., Lassen, Ulrik Niels, Le Tourneau, C., Sarker, D., Smith, C., Ohnmacht, U., Oakley, G., Patel, B. K. R., Yuen, E. S. M., Benhadji, K. A. & Rodon, J., 2018, In: Annals of oncology : official journal of the European Society for Medical Oncology. 29, 9, p. 1911-1917 7 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  8. Published

    VEGF-C sustains VEGFR2 activation under bevacizumab therapy and promotes glioblastoma maintenance

    Michaelsen, Signe Regner, Staberg, M., Pedersen, H., Jensen, K. E., Majewski, W., Broholm, H., Nedergaard, M. K., Meulengracht, C., Urup, T., Villingshøj, M., Lukacova, S., Skjøth-Rasmussen, J., Brennum, J., Kjær, Andreas, Lassen, Ulrik Niels, Stockhausen, M., Poulsen, H. S. & Hamerlik, P., 2018, In: Neuro-Oncology. 20, 11, p. 1462-1474

    Research output: Contribution to journal › Journal article › Research › peer-review

  9. Published

    Molecular profiling of short-term and long-term surviving patients identifies CD34 mRNA level as prognostic for glioblastoma survival

    Michaelsen, Signe Regner, Urup, T., Olsen, L. R., Broholm, H., Lassen, Ulrik Niels & Poulsen, H. S., 2018, In: Journal of Neuro-Oncology. 137, 3, p. 533-542 10 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  10. Published

    Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer

    Schneeweiss, A., Park-Simon, T. W., Albanell, J., Lassen, U., Cortés, J., Dieras, V., May, M., Schindler, C., Marmé, F., Cejalvo, J. M., Martinez-Garcia, M., Gonzalez, I., Lopez-Martin, J., Welt, A., Levy, C., Joly, F., Michielin, F., Jacob, W., Adessi, C., Moisan, A. & 7 others, Meneses-Lorente, G., Racek, T., James, I., Ceppi, M., Hasmann, M., Weisser, M. & Cervantes, A., 2018, In: Investigational New Drugs. 36, 5, p. 848-859 12 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  11. Published

    Mutational landscape assessed in tumor tissue and cell-free DNA during neratinib treatment of patients with HER2 mutated solid tumors

    Spanggaard, I., Oestrup, O., Bertelsen, B., Rohrberg, K. S., de Schmidt, A. Y., Tuxen, I. V., Ahlborn, L. B., Hasselby, Jane Preuss, Santoni Rugiu, Eric, Marvig, R. L., Lassen, Ulrik Niels, Nielsen, Finn Cilius, Yde, C. W. & Mau-Sørensen, M., 2018, In: European Journal of Cancer. 103, Suppl. 1, p. E142-E143 2 p.

    Research output: Contribution to journal › Conference abstract in journal › Research

Previous 1 2 Next

ID: 4952653